{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:30:50Z","timestamp":1768905050141,"version":"3.49.0"},"reference-count":65,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transthyretin cardiac amyloidosis (ATTR\u2010CA) has been recognized as an underdiagnosed and undertreated cause of heart failure with often unrecognized multiorgan involvement. Guideline development and the establishment of nonbiopsy criteria for diagnosis of ATTR\u2010CA have led to an increased rate of diagnosis and hence patients referred for therapies. ATTR is a protein misfolding disorder where the TTR tetramer disassociates into monomers which form insoluble amyloid depositions in organs, including the heart. ATTR\u2010CA can be due to autosomal dominant transmitted gene mutation or due to misfolding of wild\u2010type TTR. Prior to 2019, there were no FDA\u2010approved pharmacological treatments for ATTR\u2010CA. Understanding of ATTR\u2010CA pathogenesis has enabled development of targeted strategies with novel disease\u2010modifying therapies. Current and emerging therapies for ATTR\u2010CA include (1) TTR gene silencing (siRNA, ASO, CRISPR\/Cas9), (2) TTR tetramer stabilization, and (3) TTR amyloid fibril degradation. This review focuses on the pathophysiology of ATTR\u2010CA, diagnostic criteria, and addresses current and emerging treatments for this diverse disorder.<\/jats:p>","DOI":"10.1002\/phar.2639","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T18:59:51Z","timestamp":1634756391000},"page":"1081-1091","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-3764","authenticated-orcid":false,"given":"Alberta L.","family":"Warner","sequence":"first","affiliation":[{"name":"Division of Cardiology Veterans Affairs Greater Los Angeles Healthcare System and University of California Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx350"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.092"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701842988"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2017.07.004"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506120308998998"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1764928"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.596"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.3070"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009493"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1436048"},{"key":"e_1_2_12_18_1","unstructured":"FDA approves first\u2010of\u2010its kind targeted RNA\u2010based therapy to treat a rare disease. FDA. 2020. Accessed May 30 2021.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010its\u2010kind\u2010targeted\u2010rna\u2010based\u2010therapy\u2010treat\u2010rare\u2010disease."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1480"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035831"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.07.043"},{"key":"e_1_2_12_23_1","unstructured":"Alnylam Pharmaceuticals.APOLLO\u2010B: A Phase 3 randomized double\u2010blind placebo\u2010controlled multicenter study to evaluate the efficacy and safety of Patisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). clinicaltrials.gov;2021. Report No.: NCT03997383. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03997383."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06919-4"},{"key":"e_1_2_12_25_1","unstructured":"Alnylam Pharmaceuticals.HELIOS\u2010B: a phase 3 randomized double\u2010blind placebo\u2010controlled multicenter study to evaluate the efficacy and safety of Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). clinicaltrials.gov;2021. Report No.: NCT04153149. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04153149."},{"key":"e_1_2_12_26_1","unstructured":"Alnylam Pharmaceuticals.HELIOS\u2010B: a phase 3 randomized double\u2010blind placebo\u2010controlled multicenter study to evaluate the efficacy and safety of Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). clinicaltrials.gov;2021. Report No.: NCT04153149. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04153149."},{"key":"e_1_2_12_27_1","unstructured":"Vutrisiran receives fast track designation from FDA. Amyloidosis Research Consortium.2021. Accessed May 30 2021.https:\/\/arci.org\/vutrisiran\u2010receives\u2010fast\u2010track\u2010designation\u2010from\u2010fda\/."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_2_12_29_1","unstructured":"Drug Approval Package: Tegsedi (inotersen). Accessed May 30 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211172Orig1s000TOC.cfm."},{"key":"e_1_2_12_30_1","unstructured":"Ionis Pharmaceuticals Inc.A phase 3 global double\u2010blind randomized placebo\u2010controlled study to evaluate the efficacy and safety of ION\u2010682884 in patients with transthyretin\u2010mediated amyloid cardiomyopathy (ATTR CM). clinicaltrials.gov;2021. Report No.: NCT04136171. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04136171."},{"key":"e_1_2_12_31_1","unstructured":"Intellia Therapeutics.Phase 1 two\u2010part (open\u2010label single ascending dose (part 1) and open\u2010label single dose expansion (Part 2)) study to evaluate safety tolerability pharmacokinetics and pharmacodynamics of NTLA\u20102001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv\u2010PN).clinicaltrials.gov;2020. Report No.: NCT04601051. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04601051."},{"key":"e_1_2_12_32_1","unstructured":"The Nobel Prize in Chemistry 2020. NobelPrize.org. Accessed May 30 2021.https:\/\/www.nobelprize.org\/prizes\/chemistry\/2020\/press\u2010release\/."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi5011249"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1519507"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-10-S1-O23"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(96)88826-2"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.301273"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079589"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.09.011"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2027"},{"key":"e_1_2_12_43_1","first-page":"1","article-title":"Addendum to: Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"144","year":"2021","journal-title":"Circulation"},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","unstructured":"Tafamidis meglumine (Vyndaqel)\/Tafamidis (Vyndamax) Amyloidosis Cardiomyopathy Criteria for UseFebruary 2021. 2.https:\/\/www.pbm.va.gov\/apps\/VANationalFormulary\/.","DOI":"10.51731\/cjht.2022.382"},{"key":"e_1_2_12_45_1","unstructured":"FDA approves new treatments for heart disease caused by a serious rare disease transthyretin mediated amyloidosis. FDA. 2020. Accessed May 30 2021.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010new\u2010treatments\u2010heart\u2010disease\u2010caused\u2010serious\u2010rare\u2010disease\u2010transthyretin\u2010mediated."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.700"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"e_1_2_12_48_1","unstructured":"Eidos Therapeutics.A Phase 3 Randomized Double\u2010Blind Placebo\u2010Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE\u2010CM Trial). clinicaltrials.gov;2020. Report No.: NCT03860935. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03860935."},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.06.030"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2012.10.007"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S96893"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-74"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1593133"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-018-1887-x"},{"key":"e_1_2_12_56_1","unstructured":"Prothena Biosciences Limited.A Phase 1 Open\u2010label Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis. clinicaltrials.gov;2020. Report No.: NCT03336580. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03336580"},{"key":"e_1_2_12_57_1","unstructured":"Prothena reports positive 9 Month results from phase 1 long\u2010term extension study of PRX004 the first investigational anti\u2010amyloid immunotherapy for the treatment of ATTR amyloidosis. BioSpace. Accessed May 30. 2021.https:\/\/www.biospace.com\/article\/prothena\u2010reports\u2010positive\u20109\u2010month\u2010results\u2010from\u2010phase\u20101\u2010long\u2010term\u2010extension\u2010study\u2010of\u2010prx004\u2010the\u2010first\u2010investigational\u2010anti\u2010amyloid\u2010immunotherapy\u2010for\u2010the\u2010treatment\u2010of\u2010attr\u2010amyloidosis\/."},{"key":"e_1_2_12_58_1","unstructured":"Neurimmune AG.A Phase 1 first\u2010in\u2010human double\u2010blind placebo\u2010controlled multicenter single and multiple ascending dose study of NI006 in patients with amyloid transthyretin cardiomyopathy followed by an open\u2010label extension. clinicaltrials.gov;2021. Report No.: NCT04360434. Accessed May 27 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04360434."},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23274-x"},{"issue":"1","key":"e_1_2_12_60_1","first-page":"10","article-title":"The effectiveness and Value of Patisiran and inotersen for hereditary transthyretin amyloidosis","volume":"25","author":"Mickle K","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.045093"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1272453"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.015"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.63.6.1285"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.07.034"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00338"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2639","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:48:23Z","timestamp":1761043703000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/phar.2639"],"URL":"https:\/\/doi.org\/10.1002\/phar.2639","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"assertion":[{"value":"2021-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}